Recent Posts

CIRM Grant Sets Stage for Next Clinical Trial January 5, 2017 - Developing groundbreaking therapies can be maddeningly slow, but jCyte recently took a big step forward, receiving an $8.3 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund a phase 2b trial Read More >
Working Towards an RP Treatment December 20, 2016 - Recently, the Gavin Herbert Eye Institute at UC Irvine profiled jCyte co-founder Jing Yang, MD, PhD and retinitis pigmentosa trial participant Elaine Cain. The article highlights Dr. Yang's stem cell research in Denmark and California and how Read More >
jCyte Completes Enrollment for Phase 1/2a Safety Trial November 28, 2016 - November 28, 2016 - California-based regenerative medicine company jCyte has completed enrollment in a phase 1/2a trial to study the safety of its stem cell therapy candidate for retinitis pigmentosa (RP). The trial included 28 patients with Read More >